Emergent Biosolutions El-Hibri

June 22nd, 2009 admin

Fuad El-Hibri has filed an intention with the SEC to sell 1.1 million shares of stock:

On January 20, 2009, Emergent Biosolutions announces that Fuad El-Hibri has filed an intention with the SEC to sell 1.1 million shares of stock: 13.5 million shares had been issued to date with 47% controlled by Fuad El-Hibri. It also announced Stage II testing of vaccines for Typhoid, Hepatitis B, and Tuberculosis.

Reblog this post [with Zemanta]

Related posts:

  1. Emergent BioSolutions on Track to Complete Delivery of 14.5M Doses of BioThrax to the US Government Ahead of Schedule ROCKVILLE, Md., May 31, 2011 (BUSINESS WIRE) — Emergent BioSolutions...
  2. Singapore Health Sciences Authority Approves Emergent BioSolutions Anthrax Vaccine, BioThrax ROCKVILLE, Md., — Emergent BioSolutions Inc. (NYSE:EBS) announced on June...
  3. Emergent BioSolutions Reports Financial Results for Full Year 2010 2010 revenues of $286.2 million 2010 net income of...
  4. Emergent BioSolutions to Present at Jefferies 2011 Global Healthcare Conference in London Emergent BioSolutions Inc. (NYSE: EBS) will be webcasting its presentation...
  5. Emergent BioSolutions Reports Financial Results for First Quarter 2011 ROCKVILLE, Md., May 05, 2011 (BUSINESS WIRE) — Emergent BioSolutionsInc....

Related posts brought to you by Yet Another Related Posts Plugin.

Categories: Answer.com, BioThrax, El-Hibri Foundation, El-Hibri Peace Education, El-Hibri Peace Education Prize, Emergent BioSolutions, Entrepreneur of the Year, Fuad El-Hibri, Fuad Elhibri, Ibrahim Y. El-Hibri, Profits and Losses, Shareholders, Tuberculosis Vaccine, W. James Jackson, Washington DC, Washington Gala Tags: , , , , , , , ,
Comments are closed.